STAT+: FDA adcomm members’ ties to industry under scrutiny

Research reveals that nearly 40% of FDA advisory meetings over a 20-year period included patient or consumer representatives with ties to industry advocacy groups. This raises concerns about potential conflicts of interest in regulatory decision-making.